Overview
- 6 inspections across 5 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2018-05-15.
At a glance
Inspections
6
Sites
5
Observations
1
Career since
Apr 2013
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Exelead, Inc. | 15 May 2018 | Human Drugs | On file |
| Biocon Biologics Limited | 7 Apr 2017 | Human Drugs | On file |
| Intas Pharmaceuticals Limited | 3 Jul 2015 | Human Drugs | On file |
| Eli Lilly Kinsale Limited | 18 Mar 2014 | Human Drugs | On file |
| GlaxoSmithKline LLC | 23 Aug 2013 | Human Drugs |
Sites inspected
Exelead, Inc.Indianapolis, United States1 insp.
Biocon Biologics LimitedBengaluru, India1 insp.
Intas Pharmaceuticals LimitedMoraiya, India1 insp.
Eli Lilly Kinsale LimitedKinsale, Ireland1 insp.
GlaxoSmithKline LLCConshohocken, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Bo Chi2 shared
Reyes Candau-Chacon2 shared
Jazmine N Still1 shared
Lindsey J Brown1 shared
Michael Shanks1 shared
Daniel J Roberts1 shared
Colleen Thomas1 shared
Kalavati C Suvarna1 shared
Larry K Austin1 shared
Meisha R Sampson1 shared
Full investigator report
Get the verbatim findings behind Lakshmi Ran Narasimhan's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site